{"id":"inactivated-adjuvanted-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Injection site pain or erythema"},{"rate":"10-20","effect":"Myalgia"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Fatigue"},{"rate":"5-10","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Inactivated adjuvanted influenza vaccines contain killed influenza virus particles combined with an immunological adjuvant that amplifies the body's adaptive immune response. The adjuvant enhances antibody production and cellular immunity against the vaccine antigens, providing improved protection compared to non-adjuvanted formulations, particularly in older adults or immunocompromised populations.","oneSentence":"This vaccine stimulates the immune system to recognize and respond to influenza virus antigens, with an adjuvant to enhance the immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:46.083Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention in adults"}]},"trialDetails":[{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT01086904","phase":"PHASE2","title":"Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-11","conditions":"Renal Transplant Recipients, Immunosuppression","enrollment":122},{"nctId":"NCT06560151","phase":"PHASE2","title":"Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2024-08-21","conditions":"Influenza","enrollment":1380},{"nctId":"NCT01024400","phase":"PHASE2","title":"Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-11","conditions":"Influenza","enrollment":110},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT06125691","phase":"PHASE1","title":"Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-01-22","conditions":"Influenza, Human","enrollment":139},{"nctId":"NCT04101838","phase":"PHASE4","title":"B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-04-01","conditions":"Influenza","enrollment":50},{"nctId":"NCT06842173","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults","status":"RECRUITING","sponsor":"Butantan Institute","startDate":"2025-09-01","conditions":"Avian Influenza A Virus","enrollment":700},{"nctId":"NCT06695130","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-18","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT06695117","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-19","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT05874713","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-06-07","conditions":"Influenza, Human, Infections, Respiratory Tract Infections","enrollment":480},{"nctId":"NCT02871206","phase":"PHASE4","title":"Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children","status":"COMPLETED","sponsor":"McMaster University","startDate":"2016-11","conditions":"Influenza","enrollment":3425},{"nctId":"NCT03755427","phase":"PHASE2","title":"A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-10","conditions":"H7N9 Influenza","enrollment":560},{"nctId":"NCT03369808","phase":"PHASE1, PHASE2","title":"A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2017-12-29","conditions":"H7N9 Influenza","enrollment":360},{"nctId":"NCT04782323","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-04-13","conditions":"Influenza","enrollment":839},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT04576702","phase":"PHASE2","title":"Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-10-08","conditions":"Influenza, Human","enrollment":471},{"nctId":"NCT05501561","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-08-25","conditions":"Influenza, Human","enrollment":1056},{"nctId":"NCT06304038","phase":"","title":"Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2017-10-16","conditions":"Influenza Vaccine, Cost-Benefit Analysis","enrollment":5483},{"nctId":"NCT05981846","phase":"PHASE2","title":"A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-09-04","conditions":"SARS CoV 2 Infection, Influenza, Human","enrollment":279},{"nctId":"NCT03330132","phase":"PHASE4","title":"Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-10-07","conditions":"Influenza, Human","enrollment":1861},{"nctId":"NCT00566345","phase":"PHASE3","title":"Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2007-11","conditions":"Influenza","enrollment":3670},{"nctId":"NCT05044195","phase":"PHASE3","title":"A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-09-30","conditions":"Influenza, Human","enrollment":2044},{"nctId":"NCT06029933","phase":"","title":"Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years","status":"RECRUITING","sponsor":"Kaiser Permanente","startDate":"2023-08-17","conditions":"Influenza, Community-acquired Pneumonia, Cardiovascular Events","enrollment":960000},{"nctId":"NCT05422326","phase":"PHASE2","title":"A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-07-18","conditions":"Influenza, Human, Influenza in Birds, Respiratory Tract Infections","enrollment":260},{"nctId":"NCT05082688","phase":"PHASE2","title":"Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-09-20","conditions":"Influenza, Herpes Zoster","enrollment":148},{"nctId":"NCT03603509","phase":"PHASE4","title":"Gene Signatures of Influenza Vaccine Responses in Older Adults","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-08-27","conditions":"Influenza","enrollment":241},{"nctId":"NCT01344057","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Seasonal Influenza","enrollment":63},{"nctId":"NCT03669627","phase":"PHASE2","title":"CT18 Infant Influenza Priming Study in Vaccine Naive Infants","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-11-01","conditions":"Influenza","enrollment":159},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT03698279","phase":"PHASE2","title":"Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-09","conditions":"Influenza","enrollment":665},{"nctId":"NCT03275389","phase":"PHASE1","title":"A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-08","conditions":"Influenza, Human","enrollment":470},{"nctId":"NCT01342796","phase":"PHASE2","title":"Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Seasonal Influenza, Influenza, Influenza Due to Unspecified Influenza Virus","enrollment":84},{"nctId":"NCT03183908","phase":"PHASE4","title":"FLUAD® vs. Fluzone® High-Dose Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-08-28","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":757},{"nctId":"NCT03448705","phase":"PHASE1","title":"Safety of 4Fluart ID Suspension for Injection in Adult Subjects","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2018-01-31","conditions":"Human Influenza","enrollment":36},{"nctId":"NCT03300050","phase":"PHASE1","title":"Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2017-10-10","conditions":"Influenza, Vaccine","enrollment":65},{"nctId":"NCT03699839","phase":"PHASE2, PHASE3","title":"Reducing the Burden of Influenza After Solid-Organ Transplantation","status":"COMPLETED","sponsor":"Oriol Manuel","startDate":"2018-10-26","conditions":"Influenza, Organ Transplantation","enrollment":619},{"nctId":"NCT03330899","phase":"PHASE1","title":"Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2018-09-24","conditions":"Influenza, H7N9 Influenza","enrollment":432},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT03318315","phase":"PHASE2","title":"Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-02-20","conditions":"Avian Influenza, Influenza, Influenza Immunisation","enrollment":149},{"nctId":"NCT03314662","phase":"PHASE3","title":"Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-10-17","conditions":"Influenza, Human","enrollment":1778},{"nctId":"NCT03497845","phase":"PHASE2","title":"Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2018-03-15","conditions":"Influenza A Virus, H5N1 Subtype","enrollment":720},{"nctId":"NCT02587221","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-09-30","conditions":"Influenza","enrollment":6790},{"nctId":"NCT00971906","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza","enrollment":660},{"nctId":"NCT01003288","phase":"NA","title":"Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2009-10","conditions":"Healthy","enrollment":255},{"nctId":"NCT03467074","phase":"","title":"Role of Interferon-λ and Vaccine Response","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-09-01","conditions":"Vaccine Response Impaired, Allogeneic Stem Cell Transplantation","enrollment":200},{"nctId":"NCT02500680","phase":"PHASE1","title":"The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)","status":"UNKNOWN","sponsor":"Nova Immunotherapeutics Limited","startDate":"2015-07","conditions":"Influenza, Human","enrollment":102},{"nctId":"NCT01928472","phase":"PHASE1","title":"Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-08","conditions":"H7N9 Influenza","enrollment":402},{"nctId":"NCT02153671","phase":"PHASE2","title":"Immunogenicity of H5N1 Vaccine Following H5N2","status":"COMPLETED","sponsor":"PATH","startDate":"2014-05","conditions":"Influenza Vaccine","enrollment":43},{"nctId":"NCT02957656","phase":"PHASE1","title":"Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12","conditions":"Influenza A Virus, H7N9 Subtype","enrollment":53},{"nctId":"NCT01336166","phase":"PHASE2","title":"The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2009-07","conditions":"Influenza","enrollment":480},{"nctId":"NCT01730378","phase":"PHASE4","title":"Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-05","conditions":"Influenza","enrollment":131},{"nctId":"NCT01811823","phase":"PHASE4","title":"Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2014-03-31","conditions":"Influenza, HIV, Tuberculosis","enrollment":301},{"nctId":"NCT02586792","phase":"PHASE2","title":"H7N9 Boost in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-01-12","conditions":"Influenza","enrollment":27},{"nctId":"NCT00363077","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-02","conditions":"Influenza","enrollment":150},{"nctId":"NCT00554333","phase":"PHASE3","title":"Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-10","conditions":"Influenza","enrollment":795},{"nctId":"NCT02691130","phase":"PHASE2","title":"Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2015-11","conditions":"Influenza, Healthy","enrollment":224},{"nctId":"NCT01682369","phase":"PHASE2","title":"ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-09","conditions":"Influenza","enrollment":90},{"nctId":"NCT02362919","phase":"","title":"Influenza Vaccination Among the Elderly Individuals","status":"COMPLETED","sponsor":"Helmholtz Centre for Infection Research","startDate":"2015-02","conditions":"Influenza","enrollment":200},{"nctId":"NCT02213354","phase":"PHASE2","title":"H7N9 Mix and Match With MF59 in Healthy Elderly Persons","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-10","conditions":"Avian Influenza","enrollment":479},{"nctId":"NCT02255279","phase":"PHASE3","title":"Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2014-10","conditions":"Influenza","enrollment":287},{"nctId":"NCT00644540","phase":"PHASE2","title":"Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-11","conditions":"FLU","enrollment":89},{"nctId":"NCT00841646","phase":"PHASE2","title":"Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-12","conditions":"Prepandemic Influenza Vaccine","enrollment":343},{"nctId":"NCT00970177","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza","enrollment":812},{"nctId":"NCT00522067","phase":"PHASE2","title":"Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-06","conditions":"Influenza Disease","enrollment":52},{"nctId":"NCT00518726","phase":"PHASE2","title":"Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-06","conditions":"Influenza","enrollment":125},{"nctId":"NCT00992212","phase":"PHASE2","title":"Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza Disease","enrollment":418},{"nctId":"NCT00971100","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza","enrollment":752},{"nctId":"NCT00848029","phase":"PHASE3","title":"Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-11","conditions":"Pre-pandemic Influenza Vaccine","enrollment":240},{"nctId":"NCT01000207","phase":"PHASE2, PHASE3","title":"Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-10","conditions":"Swine-Origin Influenza A H1N1 Virus","enrollment":123},{"nctId":"NCT00519064","phase":"PHASE3","title":"Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-11","conditions":"Influenza Disease","enrollment":361},{"nctId":"NCT00996138","phase":"PHASE2, PHASE3","title":"Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-09","conditions":"Influenza","enrollment":200},{"nctId":"NCT00972816","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-09","conditions":"Influenza","enrollment":1357},{"nctId":"NCT01855945","phase":"PHASE1","title":"Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-05","conditions":"Prophylaxis of A/H3N2v Influenza","enrollment":627},{"nctId":"NCT00734734","phase":"PHASE2","title":"Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-06","conditions":"Interpandemic Influenza","enrollment":64},{"nctId":"NCT01152814","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-06","conditions":"Seasonal Influenza","enrollment":64},{"nctId":"NCT00956761","phase":"PHASE2","title":"Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-06","conditions":"Seasonal Influenza","enrollment":63},{"nctId":"NCT00973349","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-09","conditions":"Influenza","enrollment":2719},{"nctId":"NCT00973700","phase":"PHASE3","title":"Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Novel 2009 Influenza H1N1","enrollment":784},{"nctId":"NCT01052402","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2009-12","conditions":"Influenza, Avian","enrollment":684},{"nctId":"NCT00711295","phase":"PHASE3","title":"Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-08","conditions":"Influenza","enrollment":3583},{"nctId":"NCT00517517","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2007-07","conditions":"Influenza","enrollment":110},{"nctId":"NCT01774032","phase":"PHASE3","title":"H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2013-03","conditions":"Influenza","enrollment":91},{"nctId":"NCT00783926","phase":"PHASE1","title":"Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-07","conditions":"Influenza, Pandemic Influenza","enrollment":422},{"nctId":"NCT00644059","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Influenza, Human","enrollment":4902},{"nctId":"NCT01394614","phase":"","title":"Risk of Narcolepsy Associated With Administration of H1N1 Vaccine","status":"COMPLETED","sponsor":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","startDate":"2011-06","conditions":"Narcolepsy","enrollment":24},{"nctId":"NCT01368796","phase":"PHASE4","title":"Comparison of 4 Influenza Vaccines in Seniors","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-07","conditions":"Influenza Vaccine","enrollment":953},{"nctId":"NCT02151344","phase":"PHASE1","title":"Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-05","conditions":"Influenza A Virus, H7N9 Subtype","enrollment":100},{"nctId":"NCT01776541","phase":"PHASE2","title":"Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-01","conditions":"Pandemic H5N1 Influenza","enrollment":979},{"nctId":"NCT01651104","phase":"PHASE2","title":"Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-07","conditions":"Human Influenza","enrollment":63},{"nctId":"NCT01879540","phase":"PHASE2","title":"Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-07","conditions":"Human Influenza","enrollment":63},{"nctId":"NCT00848887","phase":"PHASE1","title":"A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Influenza","enrollment":410},{"nctId":"NCT01053143","phase":"PHASE3","title":"Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-01","conditions":"Influenza, Pandemic Influenza, Influenza A Virus, H1N1 Subtype","enrollment":100},{"nctId":"NCT00457509","phase":"PHASE1","title":"Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-01","conditions":"Pandemic Influenza, Influenza A Virus Infection, Orthomyxoviridae Infections","enrollment":251},{"nctId":"NCT01819155","phase":"PHASE2","title":"Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa","status":"COMPLETED","sponsor":"PATH","startDate":"2013-04","conditions":"Influenza","enrollment":296},{"nctId":"NCT00912496","phase":"PHASE1","title":"Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-06","conditions":"Influenza","enrollment":637},{"nctId":"NCT01218685","phase":"","title":"Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2010-04","conditions":"Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine, Immunogenicity of Pandemic Influenza A (H1N1)Vaccine","enrollment":1152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":76,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Inactivated adjuvanted Influenza Vaccine","genericName":"Inactivated adjuvanted Influenza Vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to recognize and respond to influenza virus antigens, with an adjuvant to enhance the immune response. Used for Influenza prevention in adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}